Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate.

@article{Pienta1997PhaseIC,
  title={Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate.},
  author={Kenneth J. Pienta and Peg Esper and Fred Zwas and Renee Krzeminski and Lawrence E. Flaherty},
  journal={American journal of clinical oncology},
  year={1997},
  volume={20 1},
  pages={36-9}
}
Prostate cancer is the most common cancer diagnosed in American men. The need to find effective means of preventing this disease is clear. Vitamin A and its analogues (retinoids) act as transcriptional regulators within the nucleus and have been tested as both preventative and therapeutic agents in human malignancy. Fenretinide (N-4-hydroxyphenyl retinamide) (4HPR) has been found to be relatively nontoxic in preclinical experiments and early clinical trials. Its toxicity and feasibility for use… CONTINUE READING
25 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…